In June 2026, the U.S. Department of Health and Human Services (HHS) launched a new initiative called Operation TrialBlazer to “strengthen U.S. leadership in clinical research, accelerate the development of lifesaving treatments, and ensure that patients have access to the most innovative therapies in the world.” This initiative is a department-wide effort across the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Advanced Research Projects Agency for Health (ARPA-H), the Office of the Inspector General (OIG), and other relevant HHS agencies and offices to eliminate unnecessary delays, duplicative data and evidence-generation requirements, and regulatory ambiguity that currently slow and disincentivize development in the U.S. HHS has identified several areas of focus to advance this effort:  

1. Modernizing regulatory requirements and processes 
2. Improving transparency for regulated entities 
3. Encouraging the adoption of more efficient practices 
4. Ensuring federal dollars are spent on adequately powered and designed trials 
5. Better utilizing existing data sources and technologies for regulatory and data-generation purposes 
6. Improving patient and participant access and engagement in clinical trials and removing disincentives preventing healthcare workers from being involved in the conduct of research 

How will the FDA support Operation TrialBlazer? 

The FDA has a leading role in advancing this mission, establishing major efforts to accelerate the initiation of early-stage, first-in-human (FIH) clinical trials and late-stage clinical development. Specifically, the FDA has committed to clarifying and streamlining requirements for Investigational New Drug (IND) applications, creating an expedited IND pilot program, exploring Institutional Review Board (IRB) reform, increasing trial access and participation, and expanding practical sponsor resources for Phase 1 trials. Several draft guidance documents released this summer reflect the broader goals of Operation TrialBlazer to modernize evidence generation and provide sponsors with greater flexibility in how they can demonstrate safety and efficacy. The table below highlights the relevant guidance documents, provides a brief description of each, and identifies the applicable stage(s) of drug development. 

These guidance documents provide new flexibilities and expectations for sponsors. While some present newer approaches across the FDA, others clarify or expand practices already used in certain contexts, particularly in oncology. Although the six guidance documents address different regulatory questions, they share several overarching themes that align closely with the goals of Operation TrialBlazer: 

Fit-For-Purpose Evidence:

Evidence is considered fit-for-purpose when the underlying data are appropriate and sufficient to address a specific regulatory question. With new guidance, the FDA clarifies how evidence can be evaluated based on its intended regulatory use, rather than sponsors defaulting to the same studies or evidentiary requirements in every circumstance. Sponsors can leverage new forms of evidence to support their applications, modernizing evidence generation while reducing unnecessary time and resource burdens. With this flexibility, the FDA still expects sponsors to demonstrate that their evidence is fit-for-purpose, including validation or quantification of models or new approach methodologies (NAMs). In oncology, where rare populations and novel therapies can make traditional evidence-generation approaches particularly challenging, a fit-for-purpose framework can provide greater clarity around when novel endpoints, biomarkers, and innovative trial designs are appropriate for supporting specific regulatory decisions. 

Weight-of-Evidence Approaches:

Various sources may contribute to the overall evidence package, with each providing complementary information of differing relevance and strength. A weight-of-evidence (WoE) approach considers these sources together, allowing sponsors to integrate multiple forms of evidence in support of regulatory decision-making. With this flexibility, the FDA expects sponsors to provide a detailed WoE assessment as part of the safety submission, which may include nonclinical and clinical data, a literature assessment of toxicology associated with the target, toxicology findings in animals and/or humans, and other relevant evidence. A WoE approach could also facilitate the integration of emerging approaches such as NAMs and real-world evidence (RWE) into safety assessments, allowing complementary evidence to be considered together rather than relying on a single study or evidence type to support regulatory decision-making. 

Leveraging Prior Knowledge to Reduce Unnecessary Studies:

Drug development programs sometimes regenerate information that is already well-established or sufficiently characterized through prior scientific or regulatory experience. These recent FDA guidance documents provide greater clarity on when sponsors may instead leverage relevant existing knowledge in their submissions. To maintain confidence in safety and efficacy, sponsors must still justify why existing evidence applies to their specific product, including considerations such as cell type, source, or intended use. For well-characterized oncology drugs, leveraging prior knowledge to reduce unnecessary or duplicative nonclinical studies could save time and resources. 

Model-Informed Decision Making:

Models such as quantitative systems pharmacology (QSP) can support starting dose selection and other drug development decisions. Still, model-based analyses have historically been viewed primarily as supportive or exploratory rather than as evidence that can directly inform regulatory decisions. Now, the FDA is moving toward recognizing models as decision-supporting tools for specific regulatory questions, creating opportunities for sponsors to integrate multiple evidence sources into a quantitative framework for decision-making when traditional evidence is limited. For oncology, where traditional animal models may not always adequately capture human biology or predict therapeutic dosing, greater acceptance and use of model-informed approaches could be particularly valuable for early clinical development. 

Earlier and More Actionable Decision-Making:

With new flexibilities come new questions about how and when sponsors should apply them in practice. Across these documents, and in FDA communications preceding their release, the agency emphasizes the importance of early and frequent interaction with sponsors to discuss innovative approaches before making pivotal development decisions. Prospective alignment with the FDA can give sponsors greater confidence that novel evidence-generation strategies are likely to meet regulatory expectations, reducing the risk of investing considerable time and resources into an approach that may not ultimately support the intended regulatory decision. Although more frequent FDA interactions can increase the time and resources required for both the FDA and sponsors, earlier engagement may encourage innovation and reduce the incentive to default to traditional evidence-generation approaches simply because they have an established regulatory precedent. Oncology drug development increasingly relies on innovative approaches, and earlier engagement with the FDA can provide greater clarity around how to deploy novel methods and development plans that can support regulatory decisions. 

Operation TrialBlazer aligns with plans for the Friends of Cancer Research (Friends) 2026 Annual Meeting: 

Operation TrialBlazer and these related regulatory initiatives provide important opportunities for sponsors to accelerate and streamline drug development. However, there is a need to operationalize some of the recommendations in these guidance documents to better address persistent challenges in drug development and ensure that regulatory processes are both rigorous and fit-for-purpose. The next challenge is translating these principles into approaches that can be applied consistently in practice while maintaining rigorous standards for patient safety and evidence quality. 

These efforts align with Friends’ mission of powering advancements in science and policy that speed life-changing treatments to patients. Our 2026 Annual Meeting will build on these themes, with a focus on early clinical trial development, including opportunities to apply risk-based and modern quantitative approaches that support efficient drug development while prioritizing patient safety. 
 

Click here to learn more about our Annual Meeting and the topics we will explore.